Biotech Values

[genisi]

Baxter, CSL Behring, and Talecris also compete in the A1PI market with products aimed at boosting a protein that protects the lungs from inflammation. [A1PI is another name for alpha-1 antitrypsin.] Talecris said its A1PI Prolastin product had a 67 percent share of sales in the U.S. in 2008 and 90 percent in the European Union.

Kamada has submitted a BLA for its I.V. alpha-1 antitrypsin, and intends to advance its inhaled version into phase III in Europe.